Trans-vac is a Marie Curie Industrial-Academic Partnership aimed to find an effective way to manage biomedical research alliances across the European continent, to achieve effective knowledge
management within an organisational context with respect to and to enhance the level of creativity occurring between and within industrial and academic biomedical organisations and generate an active
portfolio of projects with high potential to create knowledge and value. Specifically it aims to develop a range of portfolio projects that are actively managed (but not micro-managed and not
overly bureaucratic) and supported between the centres classified as:
* Fundamental research or clinical projects based on existing R&D synergies and projects requiring no extra funding to significantly advance the knowledge base (typically small
groups)
* Fundamental research or clinical projects based on newly identified R&D synergies and projects requiring extra funding to significantly advance the knowledge base (typically
medium groups extended to larger scale networks)
* Applied industrial research projects based on existing R&D synergies and projects requiring no extra funding to significantly advance the development of a potential revenue
generating product (typically small groups and performed in direct collaboration with identified companies)
* Applied industrial research projects based on newly identified R&D synergies and projects requiring extra funding to significantly advance the knowledge base (typically
medium groups and performed in direct collaboration with identified companies)The outcome being not only projects, publications, clinical research, industrial research but also a better understanding
of managing international research projects.
The core of the Trans-vac management structure is the alliance office, composed of four business/clinical managers located on site with the four scientific directors. This will represent a central
alliance office node into which the information obtained by the management research will be assimilated, structured and then presented back to the scientific and clinical members of the different
contractors. Specifically decisions will be taken on:
*Assess and finalise the different phases of the Transvac project
*Areas to optimise
*Projects to initiate or redefine based on progress
*Define end points for the pipeline of projects within the realms of resources available and necessity.
*Identify customers and clients for project portfolio
* Assess if the alliance meeting its strategic and financial goals.These meeting will be complemented by group presentations from biomedical research projects initiated amongst the
different entities to address progress, impact, need (go or not-go), discuss future plans and how to allocate resources.
print version
